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Disopyramide was administered intravenously to 54 pa- 
tients during atria1 fibrillation and predominantly pre- 
excited QRS configuration at the time of electrophysiologic 
study. All patients had Wolff-Parkinson-White syndrome 
and no patient had coexistent heart disease. The drug was 
given during sustained atrial fibrillation (n = 45) or during 
sinus rhythm before induction of atrial fibrillation for 
patients whose atrial fibrillation was self-terminating in the 
control state (n = 9). Atrial fibrillation converted to sinus 
rhythm within 15 min after disopyramide in 37 (82%) of the 
45 patients. The shortest RR intervals between two pre- 
excited cycles increased from 208 + 42 to 293 + 117 ms 
(p < 0.0001). The average RR interval of all cycles pro- 
longed from 332 f 60 to 396 + 117 ms (n = 45, p < 0.0001). 
The 9 patients in whom pre-excitation was abolished after 
the drug had a significantly longer initial shortest RR 
interval than that of the 36 patients in whom pre-excitation 
persisted (246 + 47 versus 199 + 36 ms, p = 0.0022). No 
patients developed significant hemodynamic or other ad- 
verse effects after disopyramide. 
These data support the intravenous use of disopyramide 
in patients with normal ventricular function who have 
atrial fibrillation and a predominant ventricular response 
over an accessory atrioventricular pathway. 
(J Am Co11 Cardiol1989;13:1133-7) 
Short-term pharmacologic therapy of atria1 fibrillation with a 
rapid ventricular response as a result of accessory pathway 
conduction differs markedly from therapy of atrial fibrillation 
without pre-excitation. Agents generally efficacious for 
slowing conduction over the atrioventricular (AV) node 
(digoxin, verapamil and propranolol) are ineffective or 
frankly deleterious with pre-excitation (1,2). Class IA anti- 
arrhythmic agents generally prolong the anterograde effec- 
tive refractory period of accessory pathways (3,4) and would 
be expected to slow the ventricular response and to facilitate 
spontaneous defibrillation in atrial fibrillation with pre- 
excitation. This study assesses the efficacy of intravenous 
disopyramide for short-term therapy of atrial fibrillation with 
a rapid ventricular response over an accessory AV pathway. 
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Methods 
Study patients. The study group consisted of 43 men and 
II women, aged I3 to 53 years mean ? 1 SD (31 + 12). All 
had Wolff-Parkinson-White syndrome and were given diso- 
pyramide after the development of atria1 fibrillation during a 
clinically indicated electrophysiologic study (n = 45) or had 
atrial fibrillation intentionally induced after disopyramide to 
assess its effect during atria1 fibrillation (n = 9). No patient 
had coexistent heart disease. Before study, 19 patients had 
at least one episode of spontaneous atria1 fibrillation and 4 
were resuscitated from ventricular fibrillation. 
Electrophysiologic study. The method of study of patients 
with pre-excitation in our laboratory has been described (5). 
Electrophysiologic studies were performed with patients in 
the nonsedated. postabsorptive state. All patients gave writ- 
ten and verbal informed consent before the procedure. All 
antiarrhythmic drugs were discontinued for 2.5 drug half- 
lives. Generally, three quadripolar electrodes were posi- 
tioned in the high right atrium, coronary sinus and apex of 
the right ventricle. A tripolar electrode was placed across the 
tricuspid valve to record the His bundle electrogram. Intra- 
cardiac electrograms were recorded simultaneously with 
surface leads, 1, II, III, V, and V, at a paper speed of 100 
mm/s on a 16 channel recorder (Siemens Mingograph). 
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Figure 1. Termination of atrial fibrillation before 
(A) and after (B) disopyramide. The initial RR 
interval between two pre-excited beats was 300 ms 
and pre-excitation was lost after disopyramide. 
Note that atria1 rhythm became more organized 
before restoration of sinus rhythm. I,11 = standard 
electrocardiographic leads; RA = right atria1 elec- 
trogram. 
Stimulus strength was twice diastolic threshold and stimulus 
duration was 2.0 ms. The study consisted of incremental 
atria1 and ventricular pacing and atria1 and ventricular ex- 
trastimulus testing at multiple cycle lengths. Atria1 Iibrilla- 
tion was induced with rapid atria1 pacing (cycle length 50 to 
150 ms) if it did not occur during the course of study. 
Intervals were measured over a 1 min sample of stable atria1 
fibrillation (6). The shortest RR interval between two pre- 
excited cycles (shortest RR interval) and the average RR 
interval of all cycles (average RR interval) were measured. 
Drug protocol. Only patients with a predominantly pre- 
excited QRS configuration during atrial fibrillation were 
selected. No patient received any concomitant drug before 
disopyramide. Disopyramide, approximately 1.7 mg/kg body 
weight (123 -t 35 mg) (3,7), was administered through a 
peripheral intravenous line over 5 to 10 min. The drug was 
given during atria1 fibrillation for sustained atria1 fibrillation 
(n = 45) and during sinus rhythm before reinduction of atria1 
fibrillation in patients whose atria1 fibrillation terminated 
spontaneously in the control state (n = 9). Blood pressure 
was measured by the cuff method in all patients studied. 
Plasma concentration of disopyramide was not generally 
obtained (3,4). 
Definitions. Atria1 fibrillation was considered sustained if 
it lasted >lO min or required therapy because of hemody- 
namic instability at any time. Atria1 fibrillation was defined 
as terminated by intravenous disopyramide if it reverted to 
sinus rhythm within 15 min after the drug was administered. 
If atria1 fibrillation converted to sinus rhythm within 2 min 
of drug administration, RR intervals before termination of 
the arrhythmia were not considered for comparison with 
control values. If pre-excitation disappeared after disopyra- 
mide, the average RR interval between two normal beats 
(average RR interval) was used as a conservative approxi- 
mation of the shortest RR interval for statistical purposes. 
Statistics. Data were analyzed with use of the unpaired 
Student’s t test and paired t test. All data are expressed as 
mean t 1 SD; a p value ~0.05 was considered statistically 
significant. 
Results 
Atria1 fibrillation termination. This was assessed in the 45 
of the 54 patients given disopyramide during atria1 fibrilla- 
tion. None of the patients developed significant symptoms or 
untoward hemodynamic effects after disopyramide. Blood 
pressure was obtainable during atria1 fibrillation before and 
after disopyramide in 18 patients and did not change (114 2 
15 versus 113 of: 15 mm Hg; t = 0.266, p = 0.824). A dry 
mouth or transient blurring of vision was noted infrequently. 
Atria1 fibrillation converted to sinus rhythm within 15 min 
after disopyramide in 37 (82%) of the 45 patients (Fig. 1 and 
2). Two of these patients developed ventricular fibrillation as 
a result of atria1 fibrillation with a rapid ventricular response 
(shortest RR interval = 135 and 200 ms, respectively) earlier 
in the study before disopyramide. Ventricular fibrillation 
developed at 2 and 5 min, respectively, after the onset of 
atria1 fibrillation. Both patients again developed atria1 fibril- 
lation during the same study and disopyramide given imme- 
diately successfully restored sinus rhythm in both. In four 
patients with a history of clinical ventricular fibrillation, 
sustained atria1 fibrillation was induced in three and non- 
sustained atria1 fibrillation in one. Ventricular rates were 
rapid with an initial shortest RR interval of 140, 145, 165 and 
180 ms, respectively. Atria1 fibrillation termination was 
achieved with disopyramide in all three patients with sus- 
tained atria1 fibrillation. 
Relation of initial shortest RR interval to termination of 
atrial fibrillation. Termination of atria1 fibrillation was not 
clearly related to the initial shortest RR interval. However, 
the group with termination of atria1 fibrillation had a signif- 
icantly shorter initial shortest RR interval than that of the 
group without (204 -+ 37 versus 243 2 46 ms, t = -2.52, p = 
0.015). There was no statistical difference between the two 
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Figure 2. Failure to terminate atria1 fibrillation after 
disopyramide. The shortest RR interval between two 
pre-excited beats was 210 initially (A) and prolonged 
to 280 ms after disopyramide (B). I,V, = standard 
electrocardiographic leads; other abbreviations as in 
Figure 1. 
groups with regard to dosage of disopyramide administered 
(1.54 ? 0.51 versus 1.77 t 0.41 mg/kg; t = -1.20, p = 0.24). 
Effect on shortest and average RR intervals. Disopyra- 
mide resulted in significant prolongation of RR intervals 
during atria1 fibrillation. Atria1 fibrillation terminated within 
2 min after the drug infusion in 9 of the 54 patients and 
consequently the effect of disopyramide on RR intervals 
could not be determined reliably. In the remaining 45 pa- 
tients available for analysis, the shortest RR interval in- 
creased from 208 t 42 to 293 2 117 ms (t = -6.237, p < 
0.0001) (Fig. 3). When the group with loss of pre-excitation 
during atria1 fibrillation after disopyramide (n = 9) is ex- 
cluded from the analysis, the shortest RR interval increased 
from 199 f 36 to 247 2 56 ms (t = -7.973, p < 0.0001). An 
increase in the shortest RR interval was observed in 40 (89%) 
of the 45 patients. In two patients who had developed 
ventricular fibrillation before disopyramide administration, 
the shortest RR interval prolonged from 135 to 175 ms in one 
patient and pre-excitation was lost entirely in the second 
patient after disopyramide. The average RR interval pro- 
longed from 322 it 60 to 396 2 117 ms (t = -5.615, p < 
0.0001) (Fig. 4); it decreased in six patients and remained 
unchanged in three. 
Effect of the initial shortest RR interval on magnitude of its 
prolongation after disopyramide. Loss of pre-excitation dur- 
ing atria1 fibrillation was dependent on the initial shortest RR 
interval. The group with abolition of pre-excitation (n = 9) 
had a significantly longer initial shortest RR interval than 
that of the group without abolition of pre-excitation (n = 36) 
(246 rf~ 47 versus 199 of- 36 ms; t = -3.253, p = 0.0022) 
(Fig. 5). 
Discussion 
The purpose of short-term pharmacologic therapy for 
atria1 fibrillation with a rapid ventricular rate is two-fold, 
namely, reduction in the ventricular rate to stabilize hemo- 
dynamic status and restoration of sinus rhythm. In atria1 
fibrillation without Wolff-Parkinson-White syndrome, a re- 
duction in the ventricular response can be achieved with the 
use of drugs, such as digitalis, beta-adrenergic blockers and 
verapamil. Conversion to sinus rhythm generally requires 
membrane-active drugs such as the class 1A antiarrhythmic 
agents. In the presence of pre-excitation during atria1 fibril- 
lation, treatment with digoxin (1) or verapamil(2) may result 
Figure 3. Effect of disopyramide on the shortest RR interval during 
atria1 fibrillation in 45 patients. The mean shortest RR interval 
increased from 208 to 293 ms. Three patients had no change, 
whereas two showed a slight decrease in the shortest RR interval 
after disopyramide. Open circles show patients whose pre-excitation 
was lost after disopyramide (n = 9); in these patients the average RR 
interval was used as a conservative approximation to the shortest 
RR interval. Shortest RR interval = the shortest RR interval 
between two pre-excited beats; average RR interval = average RR 
interval of all cycles. 
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Figure 4. Effect of disopyramide on average RR interval during atria1 
fibrillation. The mean average RR interval increased from 322 to 396 
ms. Open circles show patients whose pre-excitation was lost after 
disopyramide (n = 9). The average RR interval decreased slightly in 
six patients and remained unchanged in three. 
in further acceleration of the ventricular rate leading to 
hemodynamic instability and occasionally to ventricular 
fibrillation. 
Figure 5. Effect of the initial shortest RR interval on loss of 
pre-excitation during atria1 fibrillation after disopyramide. The 
group with loss of pre-excitation after the drug had a longer initial 
shortest RR interval than that of the group without loss of 
pre-excitation. 
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Effects of disopyramide on atrial fibrillation in the pre- 
excitation syndrome. Disopyramide is classified as a class 
IA agent whose electrophysiologic properties resemble 
those of procainamide and quinidine. In atria1 tissue, the 
drug produces a dose-dependent decrease in maximal veloc- 
ity upstroke (V,,,) of the transmembrane action potential 
and prolongs duration of the action potential and the effec- 
tive refractory period (8,9). These properties may account 
for antiarrhythmic action in terminating atria1 fibrillation, 
which is believed to be on the basis of reentry (10). Class 1A 
agents are successful in converting atria1 fibrillation to nor- 
mal rhythm in approximately 10% to 20% of patients with a 
variety of underlying heart diseases and its success rate is 
facilitated if duration of the arrhythmia is short and the atria 
are not enlarged (11). The high termination rate in our 
present study may therefore be related to the short duration 
of atria1 fibrillation and absence of atria1 enlargement. 
In the present study, disopyramide administered as a 
single agent successfully terminated acute atria1 fibrillation 
in 82% of the patients with Wolff-Parkinson-White syn- 
drome. Termination of atria1 fibrillation was independent of 
the initial shortest RR interval during atria1 fibrillation. Atria1 
fibrillation was terminated in all patients with a previous 
episode of ventricular fibrillation occurring during atria1 
fibrillation. 
RR intervals during atria1 jibrillation were significantly 
prolonged after drug administration; the shortest RR inter- 
val increased in 89% of our patients and the average RR 
interval in 80%. Thus, disopyramide may lead to hemody- 
namically more tolerable atria1 fibrillation in most patients, 
even if the arrhythmia fails to convert to sinus rhythm. 
Disopyramide can be considered before cardioversion unless 
the latter is urgently necessary for hemodynamic consider- 
ations. In some patients a slight acceleration of heart rate 
during atria1 fibrillation was observed after disopyramide. 
The latter is probably related to a combination of slowing of 
the ventricular response over the accessory pathway as a 
direct effect of disopyramide and an increase of the ventric- 
ular response over the AV node as an indirect (anticholin- 
ergic) effect. Alternatively, increased sympathetic stimula- 
tion due to progressive hypotension may contribute to rate 
increase (7). 
Wellens et al. (4) observed that administration of other 
class 1 agents (quinidine gluconate, procainamide and ajma- 
line) resulted in relatively less increase in anterograde re- 
fractoriness of the accessory pathway after the drug when 
the initial refractory period was very short. This occurrence 
suggested that these drugs may provide less protection 
against very rapid heart rates in the event of atria1 fibrilla- 
tion. Our data essentially supported their observation. Pa- 
tients with abolition of pre-excitation after the drug had a 
longer shortest RR interval than that of patients with per- 
sistent pre-excitation. The correlation might have been 
stronger had we included patients with slower initial ventric- 
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ular rates during atria1 fibrillation because such patients may 
have had a more dramatic clinical response after the drug. 
An excellent clinical response was generally observed 
regardless of the initial heart rate, as observed by Kerr et al. 
(3) in a smaller study. 
Clinical implications. This study was confined to patients 
with a very rapid ventricular response during atria1 fibrilla- 
tion and was not placebo controlled for ethical reasons. 
Nonetheless, the slowing of heart rate after disopyramide in 
this group was consistent and highly significant and was 
associated with a high rate of conversion to sinus rhythm. 
These data support the use of intravenous disopyramide in 
patients with normal ventricular function who have acute 
atria1 fibrillation and a rapid ventricular response over an 
accessory AV pathway. 
We thank Helen Cheung for performing the statistical analysis and Daphne 
Vigna for preparing the manuscript. 
References 
IO. Waldo AL. Mechanisms of atrial fibrillation. atrial flutter and ectopic 
atrial tachycardla. Circulation 1987:75(suppl 111):111-3740. 
I I. Halpern SW, ElIrod G. Singh BN. Mandel WJ. Efficacy of intravenous 
I. Sellers TD. Bashore TM. Gallagher JJ. Digitalis in the preexcitation 
syndrome. Analysis during atrial fibrillation. Circulation 1977;56:!60-7. 
procainamide infusion in converting atrial fibrillation to sinus rhythm: 
relation to left atrial sire. Br Heart J 19X0:44:589-95. 
1. Gulamhusein S. Ko P. Carruthers SG. Klein GJ. Acceleration of the 
ventricular response during atrial fibrillation in the Wolff-Parkinson-White 
syndrome after verapamil. Circulation 198?:65:34&54. 
3. Kerr CR. Prystowbki EN, Smith WM. Cook L. Gallagher JJ. Electro- 
physiologic effects of disopyramide phosphate in patients with Wolff- 
Parkinson-White syndrome. Circulation 19X2:65:869-78. 
4. Wellem HJJ. Bar FW, Dassen WRM. Brugada P. Vanagt EJ. Farre J. 
Effect of drugs in the Wolff-Parkinson-White syndrome. Am J Cardiol 
19X0:46:665-9. 
5. Sharma AD, Klein GJ, Guiraudon GM, Milstein S. Atrial fibrillation in 
patients with Wolff-Parkinson-White syndrome: incidence after surgical 
ablation of the accessory pathway. Circulation 19X5:7?: 161-9. 
6. Watt JH. Donner AP. McKinney CM. Klein GJ. Atrial fibrillation: 
minimal sampling interval to estimate average rate. J Electrocardiol 
1984:17:153-6. 
7. Morady F. Scheinman MM. Desai J. Disopyramide. Ann Intern Med 
19X2:96:33743. 
8. Sekiya A. Vaughan Williams AM. A comparison of the anti-fibrillatory 
actions and effects on intracellular cardiac potentials of pronethalol. 
disopyramide and quinidine. Br J Pharmacol 19632 1:473-X1. 
9. Josephson ME. Caract AR. Lau SH. Gallagher JJ. Damato AN. Electro- 
physiological evaluation of disopyramide in man. Am Heart J 1973~86: 
77 l-80. 
